Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial

Objective: This trial aimed to evaluate the glycemic control of polyethylene glycol loxenatide measured with continuous glucose monitoring (CGM) in patients with type 2 diabetes mellitus (T2DM), with the hypothesis that participants given PEG-Loxe would spend more time in time-in-range (TIR) than pa...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shuo Zhang, Chuanyan Zhang, Jingxian Chen, Feiying Deng, Zezhen Wu, Dan Zhu, Fengwu Chen, Yale Duan, Yue Zhao, Kaijian Hou
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-05-01
coleção:	Frontiers in Pharmacology
Assuntos:	polyethylene glycol loxenatide continuous glucose monitoring time-in-range type 2 diabetes glucagon-like peptide 1 receptor agonist insulin glargine
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1171399/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!